TFG Asset Management GP Ltd Has $6.74 Million Position in Annexon, Inc. $ANNX

by · The Cerbat Gem

TFG Asset Management GP Ltd increased its stake in Annexon, Inc. (NASDAQ:ANNX – Free Report) by 6.0% in the 2nd quarter, HoldingsChannel.com reports. The firm owned 2,810,000 shares of the company’s stock after acquiring an additional 160,000 shares during the period. Annexon comprises 1.1% of TFG Asset Management GP Ltd’s investment portfolio, making the stock its 14th biggest position. TFG Asset Management GP Ltd’s holdings in Annexon were worth $6,744,000 at the end of the most recent quarter.

Other hedge funds have also recently bought and sold shares of the company. Matauro LLC acquired a new stake in shares of Annexon in the 2nd quarter valued at $27,000. 49 Wealth Management LLC acquired a new position in shares of Annexon during the second quarter valued at $29,000. Vanguard Personalized Indexing Management LLC bought a new position in Annexon in the second quarter valued at about $29,000. CWM LLC boosted its holdings in Annexon by 212.9% in the second quarter. CWM LLC now owns 17,734 shares of the company’s stock valued at $43,000 after acquiring an additional 12,066 shares during the last quarter. Finally, Los Angeles Capital Management LLC acquired a new stake in Annexon in the second quarter worth about $48,000.

Annexon Price Performance

Shares of NASDAQ:ANNX opened at $5.04 on Friday. The firm’s 50 day simple moving average is $3.55 and its 200 day simple moving average is $2.84. Annexon, Inc. has a fifty-two week low of $1.28 and a fifty-two week high of $5.66. The company has a market capitalization of $602.94 million, a price-to-earnings ratio of -3.57 and a beta of 1.20.

Annexon (NASDAQ:ANNX – Get Free Report) last issued its earnings results on Monday, November 10th. The company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.34) by ($0.03). Equities research analysts expect that Annexon, Inc. will post -0.96 earnings per share for the current year.

Insider Buying and Selling at Annexon

In other Annexon news, Director Jung Choi bought 33,000 shares of the firm’s stock in a transaction on Monday, December 1st. The stock was purchased at an average cost of $4.19 per share, with a total value of $138,270.00. Following the completion of the purchase, the director owned 33,000 shares in the company, valued at approximately $138,270. The trade was a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Muneer A. Satter purchased 500,000 shares of the stock in a transaction on Wednesday, November 19th. The stock was acquired at an average price of $3.94 per share, with a total value of $1,970,000.00. Following the completion of the acquisition, the director directly owned 8,906,024 shares of the company’s stock, valued at approximately $35,089,734.56. This represents a 5.95% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders bought a total of 1,867,958 shares of company stock valued at $7,248,043 in the last three months. 11.87% of the stock is owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research analysts have issued reports on the stock. Wells Fargo & Company upped their target price on shares of Annexon from $14.00 to $27.00 and gave the company an “overweight” rating in a research report on Wednesday, November 19th. Weiss Ratings restated a “sell (d-)” rating on shares of Annexon in a report on Wednesday, October 8th. Zacks Research raised shares of Annexon from a “strong sell” rating to a “hold” rating in a research note on Monday, August 18th. Finally, HC Wainwright reiterated a “buy” rating and set a $14.00 target price on shares of Annexon in a research report on Friday, August 15th. Three research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, Annexon has a consensus rating of “Hold” and an average price target of $17.33.

Read Our Latest Stock Analysis on ANNX

Annexon Profile

(Free Report)

Annexon, Inc, a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis.

Further Reading

Want to see what other hedge funds are holding ANNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Annexon, Inc. (NASDAQ:ANNX – Free Report).